Methotrexate Timing and Influenza Vaccine Response in RA

Key Takeaways

• In healthy-donor lymphocyte experiments paired with a post-hoc rheumatoid arthritis vaccine analysis, methotrexate suppressed activated T- and B-cell responses while largely sparing resting cells.
• A brief methotrexate pulse had its strongest inhibitory effects during Days 2-3 of lymphocyte activation, supporting a narrow activation-phase window of sensitivity.
• Activated lymphocytes rapidly accumulated intracellular methotrexate polyglutamates and then cleared them quickly after drug withdrawal.
• In rheumatoid arthritis, methotrexate resumption on Days 3-4 after influenza vaccination aligned with poorer antibody responses, whereas delaying resumption for at least 1 week had little reported suppressive effect.

Weekly methotrexate dosing can overlap with the brief immune-activation period after influenza vaccination in rheumatoid arthritis, when T cells and B cells begin proliferating and generating antibody responses. That overlap matters because methotrexate can influence vaccine immunogenicity over days even though its effects on synovial inflammation are usually tracked over longer intervals. Early lymphocyte activation may be especially relevant if activated cells handle methotrexate differently from resting cells. Investigators tested that timing question in human lymphocytes and paired those experiments with clinical vaccine-response data.

Using peripheral blood mononuclear cells from healthy donors, investigators in the Jeong et al. study of methotrexate timing and influenza vaccine immunogenicity in rheumatoid arthritis activated T cells with anti-CD3/CD28 beads and B cells with CD40 ligand plus interleukin-21, then exposed them to methotrexate at 2 μM either continuously or as a 24-hour pulse across Day 1 through Day 4 activation windows. Flow cytometry tracked activation, proliferation, apoptosis, and cell-cycle progression, liquid chromatography-tandem mass spectrometry measured intracellular methotrexate polyglutamates, and expression work assessed reduced folate carrier 1 (RFC1), folylpolyglutamate synthase (FPGS), and γ-glutamyl hydrolase (GGH). A post-hoc analysis of two randomized influenza vaccine trials also stratified 318 patients with rheumatoid arthritis by the interval between vaccination and methotrexate resumption; a positive response was defined per influenza antigen as a 4-fold or greater antibody-titer rise at 4 weeks, and responses were summarized by how many vaccine antigens met that threshold.

Continuous methotrexate most clearly affected activated naive T cells, reducing mid-late S-phase progression from 16.3 ± 2.5% to 1.0 ± 0.3% and increasing apoptosis at 96 hours from 6.3 ± 2.6% to 17.6 ± 8.6%, both P < 0.0001. Activated T-cell methotrexate polyglutamates reached 601.6 ± 243.4 fmol/10^5 cells at 24 hours under continuous exposure, then fell sharply after drug withdrawal in pulse experiments. Resting lymphocytes were minimally affected, and Day 2-Day 3 pulse exposure produced the deepest functional suppression; B cells showed a similar pattern with a somewhat broader window of sensitivity.

RFC1 protein increased 6.5-fold at 48 hours after activation, FPGS rose early and then declined, and GGH protein remained largely unchanged, a pattern the authors linked to preferential methotrexate uptake and retention during early activation. In the post-hoc clinical analysis of methotrexate restart timing after influenza vaccination, methotrexate given on the day of vaccination or Day 1 had little reported effect, responses fell from Day 2 onward, were lowest on Days 3-4, and were robust when treatment resumed after 7 or more days.

The mechanistic experiments were done in a small healthy-donor system rather than in patients with rheumatoid arthritis receiving chronic methotrexate, and the vaccine-timing analysis was post hoc and descriptive after subgroup stratification. Methotrexate levels were not measured longitudinally in patient immune cells after vaccination, so the cellular pharmacology observed ex vivo was not directly confirmed in vivo. Whether the same rapid intracellular kinetics apply to tissue-resident or synovial immune cells also remains uncertain. The authors interpret the laboratory and clinical patterns together as a biologic explanation for the rapid recovery of vaccine responses after brief methotrexate interruption, without presenting that explanation as proven in patients.

The authors concluded that methotrexate exerts activation-phase-specific effects on lymphocytes, with rapid intracellular accumulation and clearance that may help explain why vaccine immunogenicity can recover after short treatment interruption in rheumatoid arthritis.

Clinician Questions

How was a positive influenza vaccine response defined in patients with rheumatoid arthritis taking methotrexate?

In the post-hoc analysis, a positive vaccine response was defined as a 4-fold or greater rise in antibody titer at 4 weeks after vaccination compared with baseline.

Which lymphocytes in this methotrexate timing study were most affected by drug exposure, and which were relatively spared?

Activated T cells and B cells showed suppressed activation, proliferation, cell-cycle progression, and survival with methotrexate exposure, whereas unstimulated resting lymphocytes were largely unaffected in the same experimental system.

Why did the authors link early lymphocyte activation to stronger methotrexate effects after vaccination?

The authors linked stronger methotrexate effects to early lymphocyte activation because activated cells rapidly accumulated intracellular methotrexate polyglutamates, reduced folate carrier 1 and folylpolyglutamate synthase increased during early activation, and the strongest functional suppression appeared during the early proliferative phase rather than immediately at stimulation onset or later in activation.